News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingKey Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Royal Bank of Canada significantly increased its stake in Intellia Therapeutics (NASDAQ: NTLA) during the first quarter, now holding 465,499 shares worth approximately $5.97 million. The company reported a quarterly loss of $0.80 per share, meeting estimates, but revenue of $7.66 million missed expectations, …
Intellia Therapeutics (NTLA) reported Q2 2026 earnings, remaining in a loss-making position, though net loss and loss per share improved year-over-year. Despite recent stock volatility and a mixed long-term record, a narrative analysis suggests NTLA is approximately 50% undervalued with a fair value of …
Intellia Therapeutics (NASDAQ: NTLA) shares surged 11% despite missing revenue forecasts in its latest quarterly report, with revenues of US$7.7m falling 41% short of expectations. Analysts have subsequently cut 2026 revenue estimates by a substantial amount to US$52.3m, although loss per share estimates remain …
Intellia Therapeutics (NTLA) stock increased by 6.2% following its Q2 earnings report, signaling positive investor sentiment despite continued losses. The company's pipeline progress, particularly with Lonvo-z completing Phase 3 trials and Nex-z trials resuming, is driving optimism. While revenue declined and losses widened year-over-year, …
State Street Corporation has disclosed a significant stake in Intellia Therapeutics (NTLA), reporting beneficial ownership of 9,234,987 shares, which represents 6.8% of the outstanding common stock. The filing, a Schedule 13G, indicates that State Street, along with its investment advisory subsidiaries, holds shared voting …
This article states that Intellia Therapeutics has filed a SCHEDULE 13G form with the SEC. The filing is categorized under "Others," indicating the nature of the report. This type of filing typically discloses beneficial ownership of shares.
Intellia Therapeutics, Inc. announced that on August 1, 2026, it awarded inducement grants to eight new employees. These grants consisted of time-based restricted stock units (RSUs) for a total of 38,200 shares of Intellia’s common stock, vesting annually over three years, and were made …
Revolution Medicines' pancreatic cancer drug daraxonrasib is seeing "significant demand" through a compassionate use program, leading analysts to raise sales projections. Intellia Therapeutics believes it has identified a genetic signature (HLA C*05:01 allele) linked to liver enzyme elevations in patients receiving its experimental gene …
Intellia Therapeutics NTLA incurred a second-quarter 2026 loss of 80 cents per share, in line with the Zacks Consensus Estimate. The loss narrowed 18.4% from the loss of 98 cents per share in the year-ago quarter. Intellia's total revenues currently comprise only collaboration revenues. …
Evercore ISI upgraded Intellia Therapeutics (NTLA) to Outperform, citing promising new data on its rare-disease therapy, nex-z, developed in partnership with Regeneron (REGN). This upgrade led to a premarket rise in Intellia's stock on Friday.
Intellia Therapeutics (NTLA) reported progress in its gene-editing programs during Q2, including positive Phase III results for lonvo-z in hereditary angioedema (HAE) and resumed enrollment for nex-z in transthyretin amyloidosis. The company is preparing a BLA for lonvo-z, targeting FDA acceptance by late 2026 …
Intellia Therapeutics, Inc.'s average 12-month price target has been adjusted to $25.56 from $25.88 by 16 analysts, with a range between $8 and $95. This new target suggests a potential upside of approximately 133% based on the August 5th closing price. Despite the slight …
This document is the quarterly report (10-Q) filed by Intellia Therapeutics. Quarterly reports contain unaudited financial statements and provide a continuing view of the company's financial condition and results of operations.
Wedbush has revised its price target for Intellia Therapeutics (NTLA) down to $12 from $17, while keeping a Neutral rating on the stock. This adjustment follows the company's recent earnings report for the second quarter and six months ended June 30, 2026, where it …
Intellia Therapeutics, Inc. (NTLA) reported its Q2 2026 financial results, showing a narrower loss per share of -$0.80, which beat analyst estimates of -$0.82. Despite this, the company's collaboration revenue declined by 46.2% year-over-year to $7.7M, and it posted a net loss of $106.6M. …
Intellia Therapeutics Inc (NASDAQ: NTLA) reported second-quarter earnings per share (EPS) that matched analyst estimates at $-0.80, but its revenue of $7.66 million fell short of the consensus estimate of $13.18 million. The company's stock price has declined by 22.14% over the last three …
Intellia Therapeutics, Inc. (NTLA) reported a Q2 loss of $0.8 per share, matching analyst expectations, but missed revenue estimates by 47.22% with $7.66 million. Despite outperforming the S&P 500 year-to-date with a 22% stock increase, the company currently holds a Zacks Rank #4 (Sell) …
Intellia Therapeutics reported a Q2 2026 net loss of $106.6 million and $628.4 million in cash. The company highlighted positive Phase 3 HAELO data for lonvo-z, showing an 87% reduction in attack rate for hereditary angioedema, and anticipates FDA acceptance for lonvo-z in H2 …
This article announces that Intellia Therapeutics Inc. filed a Form 8K on August 6th. The brief notice from Investing.com indicates that the filing is relevant to the stock market. Intellia Therapeutics Inc. (NTLA) saw a slight increase of 1.32% in its stock value mentioned …
Intellia Therapeutics, Inc. (NTLA) announced its Q2 revenue of $7.7 million, significantly missing the FactSet estimate of $13.0 million. This earnings flash provides a quick update on the company's financial performance for the second quarter.
Intellia Therapeutics reported positive Phase 3 HAELO data for its hereditary angioedema treatment, lonvoguran ziclumeran (lonvo-z), showing an 87% reduction in attacks versus placebo and no serious adverse events. The company anticipates FDA acceptance of its Biologics License Application (BLA) in the second half …
Intellia Therapeutics (NTLA) stock has seen a significant 93% decline over five years, yet its current valuation on broader checks suggests a mixed picture. While it appears overvalued based on its Price-to-Sales (P/S) ratio compared to the biotech industry, the company passes about half …
This document is the quarterly report (10-Q) filed by Intellia Therapeutics. Quarterly reports contain unaudited financial statements and provide a continuing view of the company's financial condition and results of operations.
Intellia Therapeutics Inc (NASDAQ: NTLA) is set to report Q2 2026 earnings, with a consensus EPS loss of $0.78 and an expected revenue decline. Despite a GF Value™ suggesting it's 46.1% undervalued, the company faces significant challenges including a high Price-to-Sales ratio compared to …
This article provides quotes and news related to Intellia Therapeutics (NTLA) stock options chain. It serves as a resource for investors interested in the company's stock performance and options trading.
This article from TradingKey provides a comprehensive stock analysis of Intellia Therapeutics Inc (NTLA), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company, a clinical-stage gene editing firm, shows strong revenue growth, with …
Intellia Therapeutics (NTLA) stock has experienced a significant 92.2% decline over five years, leading to a mixed valuation picture. While recent FDA clinical holds on its MAGNITUDE trials have been lifted, supporting sentiment, the company still appears expensive on a sales basis with a …
Intellia Therapeutics (Nasdaq: NTLA) announced it will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates. Interested parties can join via webcast or teleconference, with a replay available for 90 …
Search by ticker symbol or company name and select a result to open its chart.